This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary PI3 Kinase Therapeutic Antibody Development
Background of PI3 Kinase
Aberrant activation of PI3 Kinase, arising from genetic mutations, overexpression, or interactions with other signaling molecules, is closely linked to the development and progression of companion animal tumors. Many anti-tumor drugs aim to inhibit PI3 Kinase activity to halt tumor growth and spread. BioVenic has established a platform for developing veterinary PI3 Kinase therapeutic antibodies, offering comprehensive services from gene synthesis and animal immunization to antibody preparation and characterization, aiding in developing veterinary PI3 Kinase therapeutic antibodies and exploring their therapeutic potential.
Background of PI3 Kinase
| Full Name | Phosphoinositide 3 kinase |
|---|---|
| Aliases | PI3K |
| Target Profile | PI3 Kinase is the lipid kinase capable of catalyzing the D3 position phosphorylation of phosphatidylinositol. Activated by various growth factors interacting with transmembrane receptors, PI3 Kinase phosphorylates membrane phospholipids, generating the second messenger PIP3. This activation triggers related signaling pathways, extensively involved in regulating cellular proliferation, growth, survival, and metabolism. |
MoA of PI3 Kinase
PI3 Kinase is activated by external signals like growth factors, cytokines, and hormones. Among the four categories of PI3 Kinase, class I PI3 Kinase, comprising regulatory subunit p85 and catalytic subunit p110, is the most studied in cancer research. Mutations in the PI3KCA gene encoding the p110 subunit and tumor suppressor genes like PTEN are primary causes of PI3 Kinase pathway dysregulation in tumors. When this pathway shows overactivation, PI3K autophosphorylation leads to the conversion of PIP2 to PIP3, subsequently activating Akt. By activating the PI3K/Akt and mTORC1 pathways, it promotes tumor growth and cancer cell energy storage. Enhanced activity of Akt promotes phosphorylation of target genes and proteins, inhibiting apoptosis and autophagy. Additionally, dysregulated miRNAs also contribute to cancer cell proliferation.
Fig.1 Schematic diagram of the PI3K/Akt/mTOR signaling pathway involved in cancer development.1,2
Application in Veterinary Therapeutics
The activation of PI3K-related pathways leads to numerous downstream effects that promote cancer, such as in canine osteosarcoma, hemangioendothelioma, lymphoma, melanoma, and mammary carcinoma. This pathway's activation contributes to tumor survival, proliferation, and metabolic activities, playing a role in angiogenesis, tumor cell proliferation, survival, and invasion. Additionally, the sustained activation of the PI3K/Akt/mTOR signaling pathway also plays a critical role in feline-related tumors, such as cutaneous squamous cell carcinoma and mammary carcinoma, indicating that this pathway is a potential therapeutic target for feline cancer patients. Therefore, the development of specific, high-affinity therapeutic antibodies targeting PI3K and its pathways may lead to new treatments for canine and feline cancers.
Veterinary PI3 Kinase Therapeutic Antibody Development Services
Inhibiting the PI3 Kinase pathway could offer new strategies for treating tumors in companion animals like canine and feline, particularly for those resistant to conventional treatments. BioVenic has established a research and development platform equipped with various antibody development techniques, including hybridoma technology, single B cell technology, and phage display technology. We provide comprehensive veterinary PI3 Kinase therapeutic antibody development services, including species-specific antibody development to understand the biological mechanisms of companion animal tumors and bring new hope for their treatment.
Please click the link below for more information about our veterinary PI3 Kinase therapeutic antibody development services.
Fig.2 Antibody discovery and production methods: from mouse hybridoma to transgenic mice. (BioVenic Original)
Why Choose Us?
BioVenic offers one-stop services for veterinary therapeutic antibody development, from initial antigen preparation and animal immunization to later stages of antibody preparation, purification, and characterization.
Acknowledging the specificity of different animal species, we provide customized species-specific antibody development services tailored to the specific needs of each species, ensuring low immunogenicity and high affinity of therapeutic antibodies in specific species.
Throughout the process of veterinary therapeutic antibody development, our team adheres to strict quality control measures to ensure the high purity and stability of antibody samples.
The various signaling pathways of PI3 Kinase intersect to form a complex network, influencing each other and closely related to the development, treatment, and prognosis of certain cancers in companion animals. BioVenic offers veterinary PI3 Kinase therapeutic antibody development services, aiding further research into the regulation of this pathway and its interconnections with other pathways, thus deepening our understanding of PI3 Kinase's role in companion animal cancers. If you have requirements for veterinary PI3 Kinase therapeutic antibody development, please feel free to contact us for more information!
References
- Rascio, Federica, et al. "Involvement of PI3K/Akt/mTOR signalling pathways in the development of cancers." Cancers 13.16 (2021): 3949.
- Image retrieved from Figure 1 "PD-1/PD-L1-mediated inhibition of T cell activation." Rascio, Federica, et al., 2021, used under [CC BY 4.0], the image title was changed to "Schematic diagram of the PI3K/Akt/mTOR signaling pathway involved in cancer development".